Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Dingchuan is a Traditional Chinese Medicine (TCM) formulation developed by the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, specifically indicated for the treatment of respiratory syncytial virus (RSV) pneumonia in pediatric patients. The preparation is typically administered as granules or an oral liquid and is composed of a complex mixture of herbal extracts, including *Ephedra sinica*, *Scutellaria baicalensis*, and *Prunus armeniaca*. It functions through a multi-target mechanism that includes direct antiviral activity against RSV and potent anti-inflammatory effects. Research conducted by the developing institution suggests that Xiaoer Dingchuan alleviates lung injury and airway inflammation by modulating the TLR4/NF-κB signaling pathway and reducing the production of pro-inflammatory cytokines such as IL-6 and TNF-α. It is primarily utilized as a hospital preparation (院内制剂) within the Liaoning provincial healthcare system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoer Dingchuan.